| アブストラクト | INTRODUCTION: Docetaxel is an established standard therapy after osimertinib and platinum-based doublet chemotherapy (Pt-doublet) for locally advanced or metastatic non-small cell lung cancer (NSCLC) with an epidermal growth factor receptor gene (EGFR) mutation. To facilitate future therapeutic developments in these patients after treatment with osimertinib and Pt-doublet, we estimated the outcomes of currently used post-treatment therapies. METHODS: Data of patients with NSCLC who received at least one medication after osimertinib and Pt-doublet between April 2008 and August 2021 were extracted from the Medical Data Vision claims database. The duration of treatment (DoT) (first treatment after osimertinib and Pt-doublet) and overall survival (OS) were estimated. The index date was the first day on which the medication was prescribed. RESULTS: In total, 731 patients (mean age 64 years) were screened. The most frequent post-treatments were docetaxel-based chemotherapy (30.2%), immune checkpoint inhibitor (ICI) alone or in combination (17.2%), first-/second-generation EGFR-tyrosine kinase inhibitors (16.7%), osimertinib (16.3%), and Pt-doublet (5.2%). The median DoT and OS (95% confidence interval) of all post-treatments were 3.5 (3.27, 3.77) and 10.3 (9.3, 12.1) months, respectively, reflecting the median DoT (3.8 months) and OS (10.0 months) of docetaxel-based chemotherapy. Among all post-treatment regimens, ICIs resulted numerically the shortest [2.77 (2.33, 3.00) months] and osimertinib the longest [4.40 (3.47, 5.67) months] median DoT. The median OS was shortest in patients post-treated with ICIs [7.07 (5.40, 9.90) months] and longest in patients rechallenged with Pt-doublet (12.27 months), followed by patients post-treated with osimertinib (11.70 months). In a subset analysis of patients who received first-line osimertinib and second-line Pt-doublet as well as Pt-doublet immediately after osimertinib, those post-treated with ICIs had the shortest median DoT. CONCLUSION: Given the limited real-world efficacy on EGFR-mutant NSCLC resistant to osimertinib and platinum-based chemotherapy, the development of more highly potent post-treatment therapies is warranted. |
|---|
| ジャーナル名 | Advances in therapy |
|---|
| Pubmed追加日 | 2023/8/13 |
|---|
| 投稿者 | Hayashi, Hidetoshi; Nishio, Makoto; Takahashi, Michiko; Tsuchiya, Hiroaki; Kasahara-Kiritani, Mami |
|---|
| 組織名 | Department of Medical Oncology, Faculty of Medicine, Kindai University, 377-2;Ohno-higashi, Osaka-Sayama, Osaka, 589-8511, Japan. hidet31@med.kindai.ac.jp.;Department of Thoracic Medical Oncology, The Cancer Institute Hospital of JFCR,;3-8-31 Ariake, Koto-ku, Tokyo, 135-8550, Japan.;Medical Affairs Division, Janssen Pharmaceutical K.K., 3-5-2 Nishi-kanda,;Chiyoda-ku, Tokyo, 101-0065, Japan.;Integrated Market Access Division, Janssen Pharmaceutical K.K., 3-5-2;Nishi-kanda, Chiyoda-ku, Tokyo, 101-0065, Japan. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/37572265/ |
|---|
